{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT05016817",
      "OrgStudyIdInfo": {
        "OrgStudyId": "SC-10-ATG-13-08"
      },
      "Organization": {
        "OrgFullName": "The Foundation for Orthopaedics and Regenerative Medicine",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF",
      "OfficialTitle": "Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Idiopathic Pulmonary Fibrosis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 2022",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 2025",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2025",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "August 17, 2021",
      "StudyFirstSubmitQCDate": "August 17, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 23, 2021",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 4, 2022",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 5, 2022",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "The Foundation for Orthopaedics and Regenerative Medicine",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No",
      "IsUSExport": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Idiopathic pulmonary fibrosis",
      "DetailedDescription": "Studies have shown that stem cell treatment is safe for Idiopathic pulmonary fibrosis (IPF) and can improve the prognosis of afflicted patients. Patients with IPF will receive a single intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Idiopathic Pulmonary Fibrosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Idiopathic Pulmonary Fibrosis",
          "IPF",
          "stem cell treatment"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Treatment Group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Single intravenous infusion of 100 million cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: AlloRx"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "AlloRx",
            "InterventionDescription": "cultured allogeneic adult umbilical cord derived mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment Group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety (adverse events)",
            "PrimaryOutcomeDescription": "Clinical monitoring of possible adverse events or complications",
            "PrimaryOutcomeTimeFrame": "Four year follow-up"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Efficacy: Forced vital capacity (FVC)",
            "SecondaryOutcomeDescription": "It will be completed for each follow up point.",
            "SecondaryOutcomeTimeFrame": "Four year follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Oxygen saturation test",
            "SecondaryOutcomeDescription": "It will be completed for each follow up point.",
            "SecondaryOutcomeTimeFrame": "Four year follow-up"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of Idiopathic Pulmonary Fibrosis\nUnderstanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nActive infection\nActive cancer\nChronic multisystem organ failure\nPregnancy\nClinically significant Abnormalities on pre-treatment laboratory evaluation\nMedical condition that would (based on the opinion of the investigator) compromise patient's safety.\nContinued drug abuse\nPre-menopausal women not using contraception\nPrevious organ transplant\nHypersensitivity to sulfur",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Chadwick Prodromos, MD",
            "OverallOfficialAffiliation": "The Foundation for Orthopaedics and Regenerative Medicine",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Medical Surgical Associates Center",
            "LocationStatus": "Recruiting",
            "LocationCity": "St. John's",
            "LocationCountry": "Antigua and Barbuda",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Chadwick Prodromos, M.D.",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "8476996810",
                  "LocationContactEMail": "care@thepsci.com"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "31613055",
            "ReferenceType": "background",
            "ReferenceCitation": "Averyanov A, Koroleva I, Konoplyannikov M, Revkova V, Lesnyak V, Kalsin V, Danilevskaya O, Nikitin A, Sotnikova A, Kotova S, Baklaushev V. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transl Med. 2020 Jan;9(1):6-16. doi: 10.1002/sctm.19-0037. Epub 2019 Oct 15."
          },
          {
            "ReferencePMID": "31539148",
            "ReferenceType": "background",
            "ReferenceCitation": "Fishman JE, Kim GJ, Kyeong NY, Goldin JG, Glassberg MK. Intravenous stem cell dose and changes in quantitative lung fibrosis and DLCO in the AETHER trial: a pilot study. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7568-7572. doi: 10.26355/eurrev_201909_18877."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000011658",
            "ConditionMeshTerm": "Pulmonary Fibrosis"
          },
          {
            "ConditionMeshId": "D000054990",
            "ConditionMeshTerm": "Idiopathic Pulmonary Fibrosis"
          },
          {
            "ConditionMeshId": "D000005355",
            "ConditionMeshTerm": "Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafAsFound": "Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M13664",
            "ConditionBrowseLeafName": "Pulmonary Fibrosis",
            "ConditionBrowseLeafAsFound": "Pulmonary Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M27142",
            "ConditionBrowseLeafName": "Idiopathic Pulmonary Fibrosis",
            "ConditionBrowseLeafAsFound": "Idiopathic Pulmonary Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3003",
            "ConditionBrowseLeafName": "Idiopathic Pulmonary Fibrosis",
            "ConditionBrowseLeafAsFound": "Idiopathic Pulmonary Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}